News & Updates

In the treatment of adults with uncontrolled focal seizures, the long-term, open-label use of cenobamate appears to produce high rates of sustained 100-percent and ≥90-percent seizure reduction, with parallel decreases in concomitant antiseizure medication (ASM) doses, according to two separate post hoc analyses of a phase III C021 trial.

Plasma choline pathway metabolites, including choline and betaine, appear to reduce the risks of cardiovascular events and recurrent stroke, as well as offer incremental value in risk discrimination and stratification in patients with ischaemic stroke, suggests a recent study.

Nearly half of all rheumatoid arthritis (RA) patients suffer comorbidity, which has a negative impact on quality of life and mortality. At a recent scientific symposium, Professor Peter Taylor from the University of Oxford in Oxford, UK emphasized the importance of monitoring, preventing, and treating comorbidities in RA while Professor Christopher Edwards from the University Hospital Southampton in Southampton, UK focused on the impact of mental health in RA. The symposium was organized by Fresenius Kabi and held under the auspices of the Singapore Society of Rheumatology. Dr Lian Tsui Yee from Tan Tock Seng Hospital, Singapore chaired the event.

Long-term postmarketing data for adjunctive brivaracetam show that its use helps improve seizure control in patients with various epilepsy syndromes, even in those with prior exposure to levetiracetam. However, psychobehavioural adverse events (AEs) occur in one out of ten patients.

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.